23.4.2021 15:49:26 CEST | Monsenso |
Selskabsmeddelelse
Selskabsmeddelelse nr. 10-2021
København, 23. april 2021
Bestyrelsen i Monsenso A/S offentliggør hermed beslutningen om at udstede warrants med det formål at sikre at aktionærer, direktion og medarbejdere har ensrettede interesser, og at alle gør en særlig indsats for værdiskabelsen i selskabet, samt at fastholde selskabets direktion og medarbejdere.
Warrantprogrammet omfatter medarbejdere, herunder direktion, der er i uopsagt stilling og som var ansat 1. januar 2021.
Warrants modnes over 36 måneder fra 1. maj 2021 til 30. april 2024, men kun såfremt modtageren stadig er ansat i selskabet. Ikke udnyttede warrants bortfalder 31. august 2028. Der er tildelt DKK 440.000 warrants, der giver ret til tegning af nominelt DKK 44.000 aktier i selskabet.
Bestyrelsen har fastsat udnyttelseskursen til DKK 5,86 pr warrant, hvilket er mindre end markedskursen og i overensstemmelse med § 5.3 i selskabets vedtægter. Værdien af hver warrants kan beregnes til DKK 8,40 baseret på en rente på 2 % og en volatilitet af selskabets aktier på 93% (ved brug af Black-Scholes formlen).
Warrantmodtageren skal ikke betale vederlag for at tegne warrants. De modnede warrants kan udnyttes 2 gange om året efter offentliggørelse af selskabets års- og halvårsrapport i et udnyttelsesvindue på p.t. 2 uger.
Monsensos aktiekapital udgør nominelt DKK 1.339.197,50 fordelt på 13.391.975 styk aktier a DKK 0,10.
Eventuelle henvendelser vedrørende denne meddelelse bedes rettet til:
Monsenso
Chairman of the boardMaria HjorthTel. +45 25 55 63 39E-mail: maria.hjorth@gmail.com
CEO Thomas LethenborgTlf. +45 21 29 88 27E-mail: lethenborg@monsenso.com
Certified Adviser:
Norden CEF ApSJohn NordenTlf. +45 20 72 02 00E-mail: jn@nordencef.dk
Om Monsenso
Monsenso er en innovativ virksomhed, som tilbyder en digital sundhedsløsning for mentale lidelser. Vores mission er at bidrage til bedre mental sundhed til flere personer og lavere omkostninger. Vores løsning bidrager til optimering af behandlingen af psykiske lidelser og giver et detaljeret overblik over patienters mentale sundhed via indsamling af data om mental tilstand, adhærens og adfærd. Løsningen forbinder patienter, omsorgspersoner og behandlere for at muliggøre en personligt tilpasset behandling, distancebehandling samt tidlig opsporing og intervention. Baseret på vedvarende forskning og udvikling er vores team opsat på at udvikle løsninger, der passer ind i brugernes liv, øger patienters livskvalitet og forbedrer effekten af behandlingen. Få mere at vide på www.monsenso.com
Vedhæftninger
Download selskabsmeddelelse.pdf
23.4.2021 15:49:26 CEST | Monsenso |
Company Announcement
Company announcement no. 10-2021
Copenhagen, 2021.04.23
The Board of Directors of Monsenso A/S hereby announces the decision to issues warrants with the aim of ensuring that shareholders, management, and employees have uniform interests and that everyone makes a special effort to create value in the company and maintain the company’s management and employees.
The warrant program includes employees, hereunder management, who are in a non-terminated position and who were employed on January 1st, 2021.
The vesting period for the warrants is 36 months from May 1st, 2021 to April 30th, 2024, but only if the recipient is still employed by the company. Unexercised warrants expire on August 31st, 2028. DKK 440,000 warrants have been granted, giving the right to subscribe for a nominal DKK 44,000 shares in the company.
The Board of Directors has set the exercise price at DKK 5.86 per warrant, which is less than the market price and in accordance with § 5.3 of the company’s articles of association. The value of each warrant can be calculated at DKK 8.40 based on an interest rate of 2% and a volatility of the company’s shares of 93% (using the Black-Scholes formula).
The warrant holder shall not pay any compensation for the granting of the warrants. The vested warrants can be exercised twice a year after the publication of the company’s annual and half-yearly report in an exercise window of pt. 2 weeks.
Monsenso’s share capital amounts to a nominal value of DKK 1,339,197.50 divided into 13,391,975 shares of DKK 0.10.
Any inquiries regarding this notice should be directed to:
Monsenso
Chairman of the boardMaria HjorthTel. +45 25 55 63 39E-mail: maria.hjorth@gmail.com
CEO Thomas LethenborgTlf. +45 21 29 88 27E-mail: lethenborg@monsenso.com
Certified Adviser:
Norden CEF ApSJohn NordenTlf. +45 20 72 02 00E-mail: jn@nordencef.dk
About Monsenso
Monsenso is an innovative technology company offering a digital health solution for mental health and behavioral disorders. Our mission is to help provide better mental health to more people at lower costs. Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment. To learn more visit www.monsenso.com
Attachments
Download announcement as PDF.pdf
